Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensus Healthcare, Inc. filings document the financial reporting, governance and material-event disclosures of a Nasdaq-listed medical-device company focused on superficial radiotherapy systems for skin conditions. Recent Form 8-K filings furnish quarterly and annual results, non-GAAP reconciliations, business highlights, reimbursement-related disclosures, cash and debt information, and operating updates tied to SRT and IG-SRT systems.
The company’s proxy and governance filings cover annual-meeting matters, director elections, advisory executive-compensation votes, auditor ratification, board composition and independent-director appointments. Other current reports address changes in the independent registered public accounting firm, internal-control disclosures, financial-statement exhibits and related corporate-governance matters.
Sensus Healthcare reported weakening sales and compressed margins in the quarter and year-to-date. Revenue was $7.3 million in Q2 and $15.7 million for the six months, declines of 20.7% and 21.1% versus prior-year periods driven primarily by fewer units sold to a large U.S. customer. Gross profit fell to $2.9 million in Q2 and $7.3 million YTD, and gross margin narrowed to 39.7% for the quarter (from 58.7%) and 46.5% YTD (from 60.8%).
Higher operating expenses outpaced revenue reductions: G&A, selling and marketing, and R&D all increased, with R&D up 127.8% YTD due to lobbying, added headcount and next-generation product development. The company recorded a net loss of $1.037 million in Q2 and a $3.609 million net loss for the six months, compared with net income in the prior-year periods.
Liquidity remains a stabilizing factor: cash and cash equivalents were $22.2 million and the amended revolving credit facility provides $15.0 million of available borrowing capacity with no outstanding borrowings, and the company was in compliance with credit covenants. Material risks disclosed include significant customer concentration (one U.S. customer represented 56% of Q2 revenue and 78% of receivables) and an ongoing DOJ inquiry for which potential costs cannot be estimated.